CRIS Current Research Information System

ZINZANI, PIER LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.777
EU - Europa 14.566
AS - Asia 8.832
AF - Africa 811
SA - Sud America 61
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 22
Totale 47.096
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.695
GB - Regno Unito 4.229
CN - Cina 3.211
SG - Singapore 2.416
SE - Svezia 2.214
IT - Italia 2.198
DE - Germania 2.053
VN - Vietnam 1.677
IN - India 953
UA - Ucraina 718
IE - Irlanda 656
RU - Federazione Russa 626
FR - Francia 601
ZA - Sudafrica 340
EE - Estonia 309
FI - Finlandia 203
TG - Togo 202
CH - Svizzera 171
CI - Costa d'Avorio 135
JO - Giordania 126
HR - Croazia 125
ID - Indonesia 111
BG - Bulgaria 88
CA - Canada 74
BE - Belgio 70
NG - Nigeria 67
NL - Olanda 64
HK - Hong Kong 63
JP - Giappone 59
SC - Seychelles 52
IR - Iran 50
PL - Polonia 48
AT - Austria 38
GR - Grecia 38
ES - Italia 34
BR - Brasile 30
LB - Libano 29
TR - Turchia 23
AU - Australia 20
EU - Europa 18
RO - Romania 18
CL - Cile 17
LU - Lussemburgo 15
UZ - Uzbekistan 15
CZ - Repubblica Ceca 13
MY - Malesia 12
PH - Filippine 12
PK - Pakistan 11
KR - Corea 10
DK - Danimarca 9
IL - Israele 9
TW - Taiwan 8
NZ - Nuova Zelanda 7
PE - Perù 7
MX - Messico 6
SA - Arabia Saudita 6
TH - Thailandia 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
A2 - ???statistics.table.value.countryCode.A2??? 4
HU - Ungheria 4
LT - Lituania 4
TN - Tunisia 4
BD - Bangladesh 3
EC - Ecuador 3
MK - Macedonia 3
NP - Nepal 3
PT - Portogallo 3
SM - San Marino 3
AL - Albania 2
AM - Armenia 2
AR - Argentina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
GH - Ghana 2
IQ - Iraq 2
LA - Repubblica Popolare Democratica del Laos 2
NO - Norvegia 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
BY - Bielorussia 1
BZ - Belize 1
GE - Georgia 1
KE - Kenya 1
KW - Kuwait 1
KZ - Kazakistan 1
LV - Lettonia 1
LY - Libia 1
MA - Marocco 1
MT - Malta 1
MU - Mauritius 1
OM - Oman 1
PA - Panama 1
Totale 47.096
Salva come PNG Salva come JPEG
Città #
Southend 3.817
Fairfield 3.121
Singapore 2.142
Ashburn 1.684
Chandler 1.648
Woodbridge 1.504
Houston 1.458
Wilmington 1.360
Seattle 1.351
Cambridge 1.104
Princeton 1.089
Ann Arbor 1.038
Santa Clara 932
Boardman 766
Dong Ket 762
Dublin 656
Jacksonville 414
Nanjing 412
Westminster 412
Bologna 384
Berlin 335
Padova 333
Jinan 227
Lomé 202
Beijing 199
San Diego 194
Saint Petersburg 192
New York 183
Shenyang 182
Milan 171
Helsinki 157
Changsha 141
Abidjan 135
Hebei 134
Bern 127
Amman 126
Turin 125
Nanchang 124
Bremen 119
Tianjin 117
Zhengzhou 107
Jakarta 106
Mülheim 94
Los Angeles 93
Redmond 93
Guangzhou 92
Jiaxing 88
Hangzhou 85
Redwood City 85
Sofia 82
Des Moines 80
Falls Church 80
Olalla 78
Dearborn 76
Hyderabad 72
Shanghai 71
Norwalk 68
Rome 67
Abeokuta 65
Taizhou 63
Brussels 61
Florence 56
Ningbo 55
Haikou 48
Hong Kong 47
Mahé 47
Lappeenranta 46
Medford 44
Taiyuan 43
London 42
Phoenix 42
Fuzhou 41
Tokyo 41
Toronto 41
Verona 38
Bühl 37
San Venanzo 33
Shenzhen 33
Paris 31
Wuhan 31
Xi'an 28
Frankfurt am Main 25
Kunming 25
Lanzhou 25
Warsaw 25
Chicago 24
Amsterdam 22
Chengdu 20
Falkenstein 20
Foshan 20
Vienna 20
Naples 19
Frankfurt Am Main 18
Modena 18
São Paulo 18
Zanjan 18
Harbin 17
Moscow 17
Andover 15
Lausanne 15
Totale 32.488
Salva come PNG Salva come JPEG
Nome #
18F-FDG PET early after radiotherapy in lymphoma patients. 239
Consensus conference on the management of tumor lysis syndrome. 238
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 231
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 222
Biology and treatment of follicular lymphoma. 219
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 197
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 184
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 184
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 182
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 181
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 179
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 176
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 175
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 174
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 168
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 168
18 F-FDG PET in malignant lymphoma: significance of positive findings 167
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 163
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. 159
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 156
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 155
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 153
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 153
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 153
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 153
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 151
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 150
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 150
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 150
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 150
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 149
Expression of CD52 in peripheral T-cell lymphoma. 147
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 146
A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma. 146
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 146
Primary non-hodgkin’s lymphoma of bone: treatment and analysis of prognostic factors for stage I and stage II 146
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 145
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 145
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 145
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 144
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 144
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 144
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 143
RALE051: a novel established cell line of sporadic Burkitt lymphoma 143
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 143
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 142
CD30 expression in peripheral T-cell lymphomas 142
Anaplastic Large Cell Lymphoma: a critical reappraisal 141
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 139
Lymphoma: diagnosis, staging, natural history, and treatment strategies. 138
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 138
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 137
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 136
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 136
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 136
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 136
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 134
Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review 132
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 132
Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. 131
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 131
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 131
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 130
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. 130
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 130
Histopathology of B-cell chronic lymphocytic leukemia. 129
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 129
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 129
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 128
The role of mitoxantrone in the treatment of indolent lymphomas. 127
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 127
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 127
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials 127
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients 127
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 126
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper 126
Angioimmunoblastic T-Cell Lymphoma 126
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 126
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 125
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. 125
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 125
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 125
CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? 125
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 125
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 125
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 125
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 124
SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. 124
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 124
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 124
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 123
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 123
Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas. 122
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 121
Bendamustine: role and evidence in lymphoma therapy, an overview. 121
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 121
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. 120
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 120
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 120
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 120
Totale 14.519
Salva come PNG Salva come JPEG
Categoria #
all - tutte 139.265
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 139.265
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.268 0 0 0 0 0 1.327 1.504 1.640 1.751 817 461 768
2020/20216.298 1.219 467 181 233 147 429 81 325 673 278 317 1.948
2021/20228.269 901 251 567 737 812 444 178 671 307 477 1.593 1.331
2022/20238.447 973 1.102 503 1.028 698 601 280 540 1.390 301 606 425
2023/20242.799 180 449 201 270 223 374 177 180 98 278 218 151
2024/20257.043 430 2.120 1.121 963 1.791 618 0 0 0 0 0 0
Totale 48.520